Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Benzinga Healthcare Small Cap Investment Conference 2021
37 slides from Nemaura Medical's conference presentation, Sep 28, 2021
Slide 1: Benzinga Healthcare Small Cap Investment Conference
BENZINGA HEALTHCARE SMALL CAP INVESTMENT CONFERENCE 29 th September 2021 Dr Faz Chowdhury, CEO Nasdaq : NMRD
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies can sometimes be identified by use of terms such
Slide 3: Background: About the CEO
Background About the CEO… • Trained as a Drug Formulation Scientist • Masters in Microsystems and Nanotechnology, Cranfield University UK • Doctorate in Nanomedicine and Drug Delivery, University of Oxford • First patent: Super - absorbent tablets during undergraduate internship at 3M Healthcare • C
Slide 4: Introduction
Introduction We developed the world’s first Daily - Wear non - invasive Continuous Glucose Monitor (CGM) – Class 2b CE approved Medical Device. Launched: sugarBEAT ® and BEAT ® diabetes , supporting Diabetes prevention, management and reversal. Today: Launch of Beta for Mass Market consumer metaboli
Slide 5: Introduction: Today's Focus
Introduction Today’s Focus: Sales and Reimbursement strategy for sugarBEAT® Daily - Wear non - invasive Continuous Glucose Monitor (CGM) – Class 2b CE approved Medical Device. Mass Market consumer metabolic health application – MiBoKo
Slide 6: The Problem
The Problem… There are over 463 million people living with diabetes worldwide, and over $ 760 Billion was spent in the US alone in 2019 for diabetes related healthcare expenditure 1 . Obesity and Diabetes are two of the major drivers of the chronic disease epidemic The total addressable market excee
Slide 7: Our Objective: Prevent, Manage or Reverse Type 2 Diabetes
Our Objective: Prevent, Manage or Reverse Type 2 Diabetes Use our suite of technologies to improve metabolic health across the broader population
Slide 8: Our Unique Solution
UNIQUE The world’s first daily wear CGM: no other sensor technology is currently available allowing non - invasive daily use. LIFESTYLE Other competing sensors are worn for 10 - 14 days consecutively. Nemaura’s BEAT® sensors are designed for daily use – any day you choose. Our Unique Solution KNOWLE
Slide 9: Our Approach
Our Approach 1. sugarBEAT ® CGM – real time glucose monitoring. 2. BEAT ® diabetes – digital program for diabetes management and reversal, with intermittent glucose profiling. 3. Mass market consumer metabolic health program, targeting obesity, pre - diabetes and Type 2 diabetes.
Slide 10: Total Addressable Market: Diabetes Reversal
Total Addressable Market: Diabetes Reversal UK 4.8 million people with diabetes 8 One person diagnosed every 2 minutes Germany 9.5 million have diabetes 9 . 4.5 million of these 9.5 million are undiagnosed and, as a result, may be particularly at risk. U.S. 34.2 million have diabetes 6 88 million pe
Slide 11: Impact on Healthcare Cost
Impact on Healthcare Cost □ Healthcare costs for persons with Type 2 diabetes cost approximately 2.5x as much as a person without diabetes. If they experience complications, that number soars even higher 10 □ Employers and healthcare insurers are therefore resorting to programs that will provide lon
Slide 12: Product Portfolio
Product Portfolio sugarBEAT® CGM BEAT®diabetes Program MiBoKo ® Consumer Metabolic Health Program
Slide 13: sugarBEAT CGM
CE approved Class IIB Medical Device US FDA PMA approval and launch in the US anticipated by end of 2021 The world’s first daily wearable Continuous Glucose Monitor that doesn’t use needles. CE Approved Class IIb Medical Device sugarBEAT CGM
Slide 14: How it works: Apply the sensor
How it works Apply the sensor Position the daily disposable Sensor and Transmitter on your arm
Slide 15: How it works: See changes as they happen
| Good morning, J You in your target ronge © Glucose level Time 09:03 Hour oerge How it works @ See changes as they happen Helps you understand your unique glucose trend line and lifestyle choices taken.
Slide 16: How it works: BEAT diabetes
How it works YesYouCan BEAT™diabetes Better manage, take control and even prevent the onset of Type 2 Diabetes.
Slide 17: sugarBEAT and Time in Range
A critical advantage of CGM - based systems is the ability to measure the time that glucose levels are in normal range – i . e . , time in range (TIR) . Control over TIR leads to a significant reduction in the onset of complications of diabetes . The same HbA 1 C values can give vastly differing TIR
Slide 18: sugarBEAT vs. HbA1C
sugarBEAT ® vs. HbA1C 40% high range 40% in range 20% low range 70% high range 25% in range 5% low range 100% in range The same HbA1C value, yet 3 completely different TIR profiles, demonstrating the power of TIR over HbA1C as the new gold standard 11
Slide 19: sugarBEAT Testimonials
sugarBEAT ® Testimonials My Sugar Watch offered me a needle - free blood glucose monitoring solution that’s non - invasive and easy to use. I didn’t even realize I had the My Sugar watch device on my arm as it is so lightweight. It gives me the assurance that my blood sugar reading is accurate, and
Slide 20: sugarBEAT Sales Status: UK
sugarBEAT ® Sales Status: UK UK: 200,000 Sensors ordered by licensee following soft launch success. Purchase order forecast for (approximately) a further 100,000 per month for the next 2 years, totaling over 2 million sensors. Licensee selling these based on a diabetes management subscription servic
Slide 21: sugarBEAT Sales Status: ROW
sugarBEAT ® Sales Status: ROW ◆ Expecting to reveal launch plans for direct to consumer launch of sugarBEAT outside of UK, next quarter.
Slide 22: sugarBEAT Reimbursement Strategy
sugarBEAT ® Reimbursement Strategy ◆ 27 th September 2021 – Announced a deal with MSW Duo - Pack ◆ MSW - DP will purchase devices and sensors from Nemaura ◆ Devices and sensors will be included with widely prescribed diabetes medications – of which there are 2.1 million people on these medications i
Slide 23: Type 2 Diabetes prevention and management program launched in the U.S.
Type 2 Diabetes prevention and management program launched in the U.S.
Slide 24: BEAT diabetes – Components
BEAT ® diabetes – 3 Components 1. Weight loss program originally developed at the Joslin Diabetes Centre – over 12 years of clinical evidence (based on an in - clinic program, subsequently replicated using a virtual program). Sustained long term weight loss achieved without loss of muscle mass 2. pr
Slide 25: BEAT diabetes – Glucose Profiling
BEAT ® diabetes – Glucose Profiling Intermittent Glucose Profiling: Benefits 7 - point glucose profiles every 4 weeks. Patients received guidance for diet and exercise adjustments based on Self - monitoring of blood glucose (SMBG). Outcome: Significant reductions in HbA1c, weight, BMI, systolic BP,
Slide 26: BEAT diabetes: Potential Outcome for Payers
BEAT ® diabetes : Potential Outcome for Payers $1,600 $4,700 $6,600 $9,100 Healthy (No conditions) Prediabetes only Hypertension Only Diabetes Only Annual Cost per Employee On average, diabetes costs both employers and insurers over $9,000 per year. Potential savings from prescription medications al
Slide 27: BEAT diabetes: Current Status
BEAT ® diabetes : Current Status Pilot study progress to be provided in Q4 2021 together with plans for large scale adoption
Slide 28: MiBoKo.com
MiBoKo.com Metabolism is life. 87 Million people with pre - diabetes in the US Can we help them avoid becoming Diabetic using our low cost wearable glucose sensor and digital ecosystem?
Slide 29: Launching MiBoKo 'Mind Body Connect'
Launching MiBoKo ‘MIND BODY CONNECT’ A metabolic health program comprising an app and integrated glucose sensor
Slide 30: MiBoKo: A Mass-Market Consumer Product
MiBoKo : A Mass - Market Consumer Product The Centers for Disease Control and Prevention currently estimates that more than 42% of U.S. adults are obese. The risks associated with obesity are serious. Obese adults are up to 80 times more likely to get diabetes than individuals in what is considered
Slide 31: MiBoKo: Market Positioning
MiBoKo : Market Positioning • A world - first program designed to support weight loss and a better quality of life through continuous feedback on metabolic health • A bespoke app and integrated glucose sensor worn two days per month, at an affordable cost based on subscription • The free app include
Slide 32: MiBoKo: Launch Plan and Timings
MiBoKo : Launch Plan and Timings Beta program launched 29 th September 2021 offering free sensors to those who apply and are selected Innovative feature - set, with strong AI capability with continuous improvements MiBoKo will be available globally, although marketing activity will be initially focu
Slide 33: Future Product Opportunities Leveraging the BEAT Technology
CONTINUOUS LACTATE MONITORING Assists in threshold maximization in performance athletes Early identification of tissue hypoperfusion or shock for aggressive early resuscitation of critically ill patients to improve the their chances of survival BODY TEMPERATURE MONITORING Gives a more accurate and l
Slide 34: Future Product Opportunities Leveraging the BEAT Technology
ALCOHOL MONITORING Support personal health goals and provide warnings prior to driving. Provide physicians with information about individual’s drinking habits. Prevention of progression - to - alcohol - related disease DRUG MONITORING Monitoring the impact of drugs and personalized treatment plan fo
Slide 35: The Team
The Team We are building a world class team So far includes senior level appointments, with experience from companies including: Dexcom, Lifescan , Roche, Abbvie , & Eli Lilly
Slide 36: Summary
Summary 1. UK Order fulfillment for 200,000 sensors and associated devices in progress. 2. Launch in Outside - UK territories (with CE mark) in progress 3. Next steps for BEAT ® diabetes program and adoption/marketing plans for insurers and Employers in the USA to be issued next quarter 4. FDA PMA s
Slide 37: References
References https:// www.nasdaq.com /articles/everything - you - need - to - know - about - noom - 2020 - 07 - 21 25 .
Nemaura Medical — Benzinga Healthcare Small Cap Investment Conference 2021 on 6ix